Skip to main content

Lion Cinches NetGenics Acquisition

NEW YORK, Jan. 31 - Lion Bioscience has tied up its acquisition of NetGenics, the company said on Wednesday.

The acquisition, first announced two weeks ago, makes NetGenics a part of Lion's US-based operations.

 

Manuel Glynias, NetGenics' president and CEO, will become senior vice president for strategic planning at Lion, and Michael Dickson, who was chief technology officer at NetGenics, will become a the senior principal architect at Lion. Both men "will initially focus on the integration of NetGenics' DiscoveryCenter software" into Lion's product portfolio, Lion said in a statement.

 

A spokeswoman for Lion's US headquarters, in Cambridge, Mass., said that the rest of NetGenics' employees will be spared their jobs.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.